Morgan Stanley Reiterates Equalweight Rating on Solventum (SOLV)

Morgan Stanley analyst Patrick Wood reiterated an Equalweight rating and $60.00 price target on Solventum (NYSE: SOLV)

The analyst comments "Big picture - getting culture into the right place: Stepping back, management's view since the spin is that while there's considerable work to be done, the main surprise has been stronger buy-in from the employees and leaders than expected, with strong engagement. The main focus from here is shifting the company culture to be more agile (with higher R&D productivity) and healthcare focused. We sense there's still a discussion happening around the degree of reinvestment for growth relative to margins, but that the single largest priority is ultimately repositioning the group to faster growing markets and getting topline volumes going again. This always creates some debate for what 2025 EPS looks like, but we would far prefer heavy investment to aggressively reposition than half measures."

For an analyst ratings summary and ratings history on Solventum click here. For more ratings news on Solventum click here.

Shares of Solventum closed at $65.60 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades Telecom Argentina (TEO) to Overweight
• Arm Holdings (ARM) PT Raised to $475 at TD Cowen
• Digital Realty Trust (DLR) PT Raised to $225 at Truist Securities